Welcoming Molecular Medicine

Molecular Medicine is an open access journal exploring disease pathogenesis at the molecular or physiological level. Now publishing in partnership with BMC, we took the opportunity to talk to Executive Editor Margot Puerta and Managing Editor Rosamaria Ruggieri about the history of the journal, their reasons for publishing with BMC and their vision for the future of Molecular Medicine.

Can you tell us a bit more about the history of Molecular Medicine?

Molecular Medicine was introduced in 1994 by Anthony Cerami, PhD and Kenneth Warren, MD. The goal was to create a forum through which biomedical researchers and clinicians could communicate recent discoveries to a multidisciplinary audience interested in understanding and curing disease. The field and the journal have both excelled, with several significant advances published in Molecular Medicine.

In 2013, we established two prizes to honor accomplishments in the field of molecular medicine.

The annual Ross Prize in Molecular Medicine (LINK) highlights an investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. We look forward to hearing this year’s winner, Baylor College of Medicine’s Huda Zoghbi, MD, present at the Award Ceremony and Mini-Symposium in June.

The Anthony Cerami Award in Translational Medicine (LINK) honors investigators who have created a fundamental innovation necessary for molecular medicine to advance into clinical practice. The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Recipients are invited to publish a monograph of their work that inspired or produced the clinical product(s). The monographs, in the voice of the discoverer, permanently document their stories and inspire future innovators to advance medicine. A 2018 winner will be announced later this year.

What made you choose BMC as a publishing partner?

Over the past twenty years we have seen the publishing world evolve from print to digital and from subscription to open access. We chose to partner with BMC because of their foundation in open access publishing and their strong content delivery systems and strategies. Continuous advances in technology allow discoveries in basic understanding of disease pathogenesis to occur rapidly. Our partnership with BMC will allow us to disseminate content more quickly and in a user-friendly way.

What is your vision for the future of the journal, Molecular Medicine?

Molecular Medicine will continue to build this journal as an exchange of fresh ideas in  basic science and clinical practice. We look forward to supporting authors from diverse scientific and clinical subject areas, with the goal of improving disease diagnosis, treatment, and prevention.

View the latest posts on the Research in progress blog homepage